Third revision of the guideline on hypertension of the Dutch College of General Practitioners;NHG-standaard hypertensie

Huisarts en Wetenschap

Volumn 46, Issue 8, 2003, Pages 435-449

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ATENOLOL; BENZTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; METOPROLOL; NITRENDIPINE; THIAZIDE DIURETIC AGENT;

COMORBIDITY; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0042327802     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (169)

1. Herziening Richtlijn Hoge bloeddruk. Utrecht/Den Haag: Kwaliteitsinstituut voor de Gezondheidszorg CBQ/Nederlandse Hartstichting, 2000.
2. Rutten GEHM, Verhoeven S, Heine RJ, De Grauw WJC, Cromme PVM, Reenders K, et al. NHG-Standaard Diabetes mellitus type 2. Huisarts Wet 1999;42:67-84.
3. MacMahon S. Blood pressure and the risk of cardiovascular disease. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell Scientific Publications, 1994:46-57
4. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. Part I. Effect of prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. Lancet 1990;335:765-74.
5. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and generalizability of randomized trials JAMA 1994;272:1932-8.
6. Guidelines subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
7. Herziening Richtlijn Hoge bloeddruk Utrecht/Den Haag: Kwaliteitsinstituut voor de Gezondheidszorg CBQ/Nederlandse Hartstichting, 2000.
8. Mennen LI, Witteman JCM, Geleijnse JM, Stolk RP, Visser MC, Grobbee DE. Risicofactoren voor hart- en vaatziekten bij ouderen; het ERGO-onderzoek. Ned Tijdschr Geneeskd 1995;139:1983-8.
9. Van den Berg PJ. Preventive care in the elderly. Studies on cardiovascular disease and hearing loss [Proefschrift]. Rotterdam: Erasmus Universiteit Rotterdam, 1999.
10. Herziening Richtlijn Hoge bloeddruk Utrecht/Den Haag: Kwaliteitsinstituut voor de Gezondheidszorg CBO/Nederlandse Hartstichting, 2000.
11. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart study: a cohort study. Lancet 2001;358:1682-6
12. Yarows SA, Julius S, Pickering TG. Home blood pressure monitoring. Arch Int Med 2000;160:1251-7.
13. Thijs L, Staessen JA, Celis H, De Gaudemaris R, Imai Y, Julius S, Fagard R. Reference values for self-recorded blood pressure. A meta-analysis of summary data. Arch Intern Med 1998;158:481-8.
14. Thijs L, Staessen JA, Celis H, Fagard R, De Cort P, De Gaudemaris R, et al. Self-recorded blood pressure in normotensive and hypertensive subjects: a meta-analysis of individual patient data. Blood Press Monit 1999;4:77-86.
15. Asmar R, Zanchetti A, on behalf of the organizing committee and participants. Guidelines for the use of self-blood pressure monitoring: a summary report of the first international Consensus Conference. J Hypertens 2000;18:493-508
16. Beltman FW, Van der Meer K, Fennema MA. Do diagnostiek van wittejashypertensie door middel van thuisbloeddrukmeting. Huisarts Wet 2000;43:155-8.
17. O'Brien E, Pickering T, Asmar R, Myers M, Parali G, Staessen J. et al., on behalf of the organizing Working Group on Blood Pressure Monitoring of the European Society of Hypertension. International protocol for validation of blood pressure measuring devices in adults. Blood Press Monit 2002;7:3-17.
18. www.hyp.ac.uk/bhs/geraadpleegd op 13 augustus 2002.
19. Asmar R, Zanchetti A, on behalf of the organizing committee and participants. Guidelines for the use of self-blood pressure monitoring: a summary report of the first International Consensus Conference. J Hypertens 2000;18:493-508.
20. Kannel WB, Gordon R, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham study. Am J Cardiol 1971;27:335-46.
21. Stamler J, Stamler R, Neaton J. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993;153:598-615.
22. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group Serum cholesterol, blood pressure, cigarette smoking, and death form coronary heart disease: overall findings and differences by age for 316099 white men. Arch Intern Med 1992;152:56-64.
23. Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002;162:577-81.
24. Benetos A, Thomas F, Safar ME, Bean KE, Guize L. Should diastolic and systolic blood pressure be considered for cardiovascular risk evaluation: a study in middle-aged men and women. J Am Coll Cardiol 2001;37:163-8.
25. Domaski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, et al., for the MRFIT research group. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the multiple risk intervention trial (MRFIT). JAMA 2002;287:2677-83.
26. Antikainen RL, Jousilahti P, Vanhanen H, Tuomilehto J. Excess mortality associated with increased pulse pressure among middle-aged men and women is explained by high systolic blood pressure. J Hypertens 2000;18:417-23.
27. Deedwania PC. The changing face of hypertension. Is systolic blood pressure the final answer? [Editorial] Arch Intern Med 2002;162:506-8.
28. Herziening Richtlijn Hoge bloeddruk Utrecht/Den Haag: Kwaliteitsinstituut voor de Gezondheidszorg CBO/Nederlandse Hartstichting, 2000.
29. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 1994;272:1932-8.
30. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993;15:967-78
31. Pearce KA, Furberg CD, Rushing J. Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. Arch Fam Med 1995;4:943-50.
32. Herziening Richttlijn Noge bloeddruk Utrecht/Den Haag: Kwaliteitsinstituut voor de Gezondheidszorg CBO/Nederlandse Hartstichting, 2000.
33. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction (AMIS). JAMA 1980;243:661-9
34. PROGRESS collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with stroke or previous transient ischaemic attack. Lancet 2001;358:1033-41.
35. Kannel WB. The Framingham Study: Its 50-year legacy and future promises. J Atheroscler Thromb 2000;6:60-6.
36. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.
37. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart J 1998;80(suppl):S1-29.
38. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000;21(5):365-70.
39. Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999;138:205-10.
40. Silberberg JS, Wlodarczyk J, Fryer J, Robertson R, Hensley MJ. Risk associated with various definitions of family history of coronary heart disease. The Newcastle Family history Study II. Am J Epidemiol 1998;147:1133-9
41. Montgomery AA, Fahey T, Peters TI, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care randomised controlled trial. BMJ 2000;320:686-90.
42. Wood D, DeBacker G, Faergeman Q, Graham I, Mancia G, Pyörä lä K, together with members of the Task Force Prevention of coronary heart disease in clinical practice - Recommendations of the second joint task force of European and other Societies on Coronary prevention. Eur Heart J 1998;19:1434-503.
43. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ 2000;320:709-10.
44. Wallis EJ, Ramsay LE, UI Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, Yeo WW. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000;320:671-6.
45. Ramsay LE, Williams B, Johnston DG, MacGregor GA, Poston L, Potter IF, et al. Guidelines for management of hypertension report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.
46. Wright IM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? I: Thiazide diuretics. Can Med Assoc J 2000;163:57-60
47. Wright JM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers. Can Med Assoc J 2000;163:188-92.
48. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-7.
49. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor of calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
50. Appel LJ. The verdict from ALLHAT - Thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002;288:3039-42
51. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jernnings GLR, et al., for the Second Australian Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
52. Frohlich ED. Treating hypertension - what are we to believe? New Engl J Med 2003;348:639-41.
53. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64
54. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
55. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised triai against atenolol. Lancet 2002;359:1004-10.
56. Wiersma TJ, Grundmeijer H, Prins A, Thomas S, Walma E, namens het Nederlands Huisartsen Genootschap. Behandeling van hypertensie na de LIFE-studie: Eén zwaluw maakt nog geen zomer. Htttp://www.artsennet.nl/nhg geroadpleegd 30 september 2002.
57. Montgomery L. Losartan more effective than atenolol in hypertension with left ventricular hypertrophy. J Fam Pract 2002;51:599.
58. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64
59. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64
60. Pahor M, Psaty BM, Alderman MH, Applegate WB, Wiliiamson ID, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356:1949-54.
61. McCarthy M. US NIH issues warning on nifedipine. Lancet 1995;346:689-90.
62. Furberg CD, Psaty BM, Meyer IV. Nifedipine: dose related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
63. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weis NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
64. Braun S, Boyko V, Behar S, Reicher-Reiss H, Shotan A, Schlesinger Z, et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort stndy of 11,575 patients. J Am Coll Card 1996;28:7-11.
65. Ad Hoc Subcommitee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997;15:105-15.
66. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Major cardiovascular events in hypertensive patients randomized to doxazozin vs chlortalidone. JAMA 2000;283:1967-75
67. Campbell NR, McKay DW. Accurate blood pressure measurement: why does it matter? Can Med Assoc J 1999;161:277-8.
68. Bakx JC, Netea RT, Van den Hoogen HJM, Oerlemans G, Van Dijk R, Van den Bosch WJHM, et al. De invloed van een rustperiode op de bloeddruk. Huisarts Wet 1999;42:53-6.
69. McAlister FA, Straus SE. Evidence based treatment of hypertension. Measurement of blood pressure: an evidence based review. BMJ 2001;322:908-11.
70. ABC of hypertension Blood pressure measurement. Part I. Sphygmomanometry: factors common to all techniques. BMJ 2001;322:981-5.
71. Netea RT. Blood pressure measurement: practical aspects of the procedure [Proefschrift]. Nijmegen: Katholieke Universiteit Nijmegen, 2002.
72. Beevers G, Lip GYH, O'Brien E. ABC of hypertension. Blood pressure measurement Part II, Conventional sphygmomanometry technique of auscultatory blood pressure measurement. BMJ 2001;322:1043-7.
73. McAlister FA, Straus SE. Evidence based treatment of hypertension. Measurement of blood pressure: an evidence based review. BMJ 2001;322:908-11.
74. Harrison JEG, Roth GM, Hines JEA. Bilateral indirect and direct arterial pressures. Circulation 1960;22:419-36
75. Gordon T, Sorlie P, Kannel W. Problems in the assessment of blood pressure: The Framingham study. Int J Epidemiol 1976;5:327-34
76. Engbersen R, Smits P, Lenders JWM, Thien Th. Enkelvoudige bloeddrukmeting bij een controlebezoek wegens hypertensie leidt vaker tot beteidscaanpassing dan multipele metingen. Ned Tijdschr Geneeskd 1994;138:241-5.
77. Shepard DS. Reliability of blood pressure measurements: Implications for designing and evaluating programms to control hypertension. J Chron Dis 1981;34:191-209.
78. Beevers DG. Blood pressures that fall on rechecking. BMJ 1982;284:71-2.
79. Brueren MM, Dinant GJ, Schouten BJ, Van Ree JW. Hypertensiediagnostiek door de huiscarts: metingen volgens de NHG-standaard vergeleken met ambulante bloeddrukmeting. Ned Tijdschr Geneeskd 1995;139:278-82
80. Brueren MM, Petri H, Van Weel C, Van Ree JW. How many measurements are necessary in diagnosing mild to moderate hypertension? Fam Pract 1997;14:30-5.
81. Brueren M, Petri H, Schouten H, Van Weel C, Van Ree J. Are four duplicate remeaserements sufficient for diagnosing and hypertension? J Hum Hypertens 1996;10:349-52.
82. Brueren MM, Schouten HJ, De Leeuw PW, Van Montfrans GA, Van Ree JW. A series of self-measurements by the patient is a reliable alternative to ambulatory blood pressure measurement. Br J Gen Pract 1998;48:1585-9
83. Stergiou GS, Skeva II, Zourbaki AS, Mountokalis TD. Self-monitoring of blood pressure at home: how many measurements are needed? J Hypertens 1998;16:725-31.
84. Pickering TG. White coat hypertension: time for action. Circulation 1998;97:1834-6.
85. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D, et al. Response to antihypertense therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000;02:1139-44.
86. Moser M. White-coat hypertension - to treat or not to treat. A clinical dilemma. Arch Intern Med 2001;161:2655-7.
87. Grandi AM, Broggi R, Colombo S, Santillo R, Imperiale D, Bertolini A, et al. Left ventricular changes in isolated office hypertension. A blood pressure-matched comparison with normotension and sustained hypertension. Arch Intern Med 2001;161:2677-81.
88. O'Brien E, Beevers G, Lip GYH, ABC of hypertension. Blood pressure measurement. Part III. Automated sphygmomanometry: ambulatory blood pressure measurement. BMJ 2001;322:1110-4.
89. Q'Brien E, Beevers G, Lip GYH, ABC of hypertension. Blood pressure measurement. Part IV. Automated sphygmomanometry: self-blood pressure measurement. BMJ 2001;322:1167-70.
90. Doll R, Peto R, Wheatly K, Gray R, Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11.
91. Kawachi J, Colditz GA, Stampfer MI, Willett WC, Manson JE, Rosner B, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med 1994;154:169-75.
92. Robbins AS, Manson IE, Min-Lee I, Satterfield S, Hennekens CH. Cigarette smoking and stroke in a cohort of US male physicians. Ann Intern Med 1994;120:458-62.
93. NHG-DKB-cahier Stoppen met roken. Utrecht: NHC, 2000.
94. Seelen MAJ, Meijer PHEM, Braun J, Swinkels LMWJ, Waanders H, Meinders AE. Hypertensie door dropgebruik. Ned Tijdschr Geneeskd 1996;140;2632-5
95. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300
96. Anonymous. Hypertensive effect of NSAID's. Rev Prescrire 1995;15:268
97. Heerdink ER. Clustering of drug use in the elderly: population-based studies info prevalence and outcomes [Proefschriftl. Utrecht: Universiteit van Utrecht, 1995.
98. Commissie Farmaceutische Hulp. Farmacotherapeutisch Kompas 2003. Amstelveen: College voor Zorgverzekeringen, 2003.
99. Commissie Aanvullende Diagnostiek. Diagnostisch Kompas 2003. Amstelveen: College voor Zorgverzekeringen, 2003
100. Commissie Farmaceutische Hulp. Farmacotherapeutisch Kompas 2003 Amstelveen: College voor Zorgverzekeringen, 2003.
101. Nederlandse Hartstichting. Homocysteïne ert hart- en vaatziekten Een publicatie van de Nederlandse Hartstichting over de diagnostiek, opsporing, behandeling en epidemiologie van hyperhomocysteinemie in relatie tot hart- en vaatziekten. Den Haag: Nederlandse Hartstichting, 2001.
102. Van Binsbergen JJ, Verschuren WMM, Blom HJ, Hyperhomocysteïnemie: opsporen en behandelen? Huisarts Wet 2002;45:406-9.
103. Brattström L, Wilcken DEL. Homocysteine and cardiovascular disease: cause of effect? Am J Clin Nutr 2000;72:315-23.
104. Wiersma TJ, Assendelft WII. Behandeling van matig verhoogde homocysteïnespiegels is prematuur. Huisarts Wet 2002;45:409-10
105. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. NEJM 1990;322:1561-6
106. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, De Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study. Losartan intervention for endpoint reduction in hypertension. Hypertension 1998;32:989-97.
107. Van de Hoogen JPH, Van Kruijsdifk MCM, Van Ree JW, Mokkink HG, Thien T, Van Weel C. The prevalence of left ventricular hypertrophy as assessed by elektrocardiogram in treated hypertensive persons in general practice. J Hum Hypertens 1993;7:473-77
108. Berkin KE, Ball SG. Essential hypertension: the heart and hypertension. Heart 2001;86:467-75.
109. Dunn FG, Pfeffer MA. Left ventricular hypertrophy in hypertension. NEJM 1999;340:1279-80.
110. Dijkstra RF, Van Schayck CP, Bakx JC, Thien T, Verheugt TW, Mokkink HG, Linkerventrikel-hypertrofie, verschillen in diagnostische en prognostische waarde van elektrocardiografie en echocardiografie. Ned Tijdschr Geneeskd 1997;11:1969-72.
111. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkeley BL, Foss A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001;72:107-11.
112. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000;18:1465-75.
113. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
114. Postma CT, Thien Th. Diagnostiek en therapie van hypertensie met nierarteriestenose. Ned Tijdschr Geneeskd 1996;140:2114-8.
115. Gordon RD. Mineralocorticoid hypertension. Lancet 1994;344:240-3.
116. Herziening Richtlijn Hoge bloeddruk Utrecht/Den Haag: Kwaliteitsinstituut voor de Gezondheidszorg CBQ/Nederlandse Hartslichting, 2000.
117. Thun MJ, Peto R, Lopez AD, Monaco JN, Henley SI, Heath CW Jr, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997;337:1705-14.
118. Beilin LJ, Paddey IB, Burke V. Alcohol and hypertension - kill or cure? J Hum Hypertens 1996;10:S1-5.
119. Xin X, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38:1112-7.
120. Campbell NR, Ashley MI, Carruthers SG, Lacourciere Y, McKay DW. Lifestyle modifications to prevent and control hypertension. 3. Recommendations on alcohol consumption. Can Med Assoc J 1999;160:S13-20.
121. Mulrow CD, Chiquette E, Angel L, Cornell J, Summerbell C, Anagnostelis B, et al. Dieting to reduce body weight for controlling hypertension in adults. Cochrane Database Syst Rev 2000;2:CD000484.
122. Metz JA, Stern JS, Kris-Etherton P, Reusser ME, Morris CD, Hatton DC, et al. A randomized controlled trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000;160:2150-8.
123. Stevens VJ, Obarzonek E, Cook NR, Lee IM, Appel LI, Smith West D, et al. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med 2001;134:1-11.
124. Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Clements G, Capps N, et al. Reduced or modified dietary fat for preventing cardiovascular disease (Cochrane Review). The Cochrane Library, issue 4, 2000. Oxford: Update Software
125. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-24.
126. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001;344:3-10.
127. Messerli FH. Salt and hypertension. Arch Intern Med 2001;116:505-6.
128. Van Bommel EFH. Zoutgevoeligheid en hypertensie. Ned Tijdschr Geneeskd 2003;147:240-4.
129. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomised trials. Implications for public health. J Hum Hypertens 2002;16:761-70.
130. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Folmann D, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997;277:1624-32.
131. Halbert JA, Silagy CA, Finucane P, Withers RT, Hamdorf PA. The effectiveness of exercise training in lowering blood pressure: a meta-analysis of randomised controlled trials of 4 weeks of longer. J Hum Hypertens 1997;11:641-9.
132. Ebrahim S, Davey Smith G. Lowering bloodpressure: a systematic review of sustained non-pharmacological interventions. J Public Health Med 1998;20:441-8
133. Cooper AR, Moore LAR, McKenna I, Riddoch CI. What is the magnitude of blood pressure response to a programme of moderate intensity exercise? Randomised controlled trial among sedentary adults with unmedicated hypertension. Br J Gen Pract 2000;50:958-62.
134. Engstom G, Hedblad B, Janzon L. Hypertensive men who exercise regularly have lower rate of cardiovascular mortality. J Hypertens 1999;17:737-42.
135. Hu FB, Stampfer MI, Colditz GA, Ascherio A, Rexrode KM, Willett WC, et al. Physical activity and risk of stroke in women. JAMA 2000;283:2961-7.
136. Ruwaards D, Kramers PGN, redacteuren. Volksgezondheid toekomstverkenning 1997. De som der delen, Utrecht: Elsevier/De Tijdstroom, 1997.
137. Birkenhäger WH, De Leeuw PW. Survival of the fittest: invloed van geregelde lichaamsbeweging op gezondheid en levensverwachting. Ned Tijdschr Geneeskd 2002;146:1479-82.
138. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000;342:454-9.
139. Linden W, Lenz JW, Con AH. Individualized stress management for primary hypertension. A randomized trial. Arch Intern Med 2001;161:1071-80.
140. Garcia-Vera MP, Labrador FJ, Sanz J. Stress-management training for essential hypertension. A controlled study. Appl Psychophysiol Biofeedback 1997;22:261-83.
141. Johnston DW, Gold A, Kentish J, Smith D, Vallance P, Shah D, et al. Effect of stress management on blood pressure in mild hypertension. BMJ 1993;306:963-6.
142. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
143. Lenders JWM, Hoefnagels WHL, Thien TH. Orthostatische hypotensie bij bejaarden. Ned Tijdschr Geneeskd 1990;134:1252-4
144. Raiha I, Luutonen S, Piha J, Seppänen A, Toikka T, Sourander L. Prevalence, predisposing factors and prognostic importance of postural hypotension. Arch Intern Med 1995;155:930-5.
145. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruytere M, et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly. Lancet 1985;1:1349-54.
146. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet 1991;338:1281-5.
147. MRC Working Party Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-11.
148. Commissie Farmaceutische Hulp. Farmacotherapeutisch Kompas. Amstelveen: College voor Zorgverzekeringen, 2003.
149. Humphreys GS, Delvin DG. Inefectiveness of propanolol in hypertensive Jamaicans. BMJ 1968;11:601-3.
150. Seedat YK. Trial of atenolol and chlortalidone for hypertension in black South Africans. BMJ 1998;281:1241-3.
151. Wassertheil-Smoller S, Davis BR, Overman AS, Blaufox MD, Lanford HG, Wylie-Rosett J, et al. The Taim Study: sex-race differences in effects of die and drugs on cardiovascular risk. Cardiovascular Risk Factors 1991;1:3-11.
152. Venter CP, Joubert PH, Venter HL, Muntingh GL, Du Plooy WJ. Penbutolol in the treatment of mild to moderate essential hypertension in black South Africans. J Clin Pharmacol 1990;30(6):533-7.
153. Matersen BJ, Reda DI, Cushman WC. Department of veterans affairs single-drug therapy of hypertension study. Revised figures and new data. Am J Hypertens 1995;8:189-92
154. Grimm RH, Grandits GA, Flock JM. Are black and white hypertensives really different? ABC Digest of Urban Cardiology 1997;6:10-6.
155. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:11769-76
156. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7
157. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized controlled clinical trials. J Am Coll Cardiol 1997;30:27-34.
158. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 1996;334:1349-55.
159. Sharpe N. Benefit of β-blockers for heart failure: proven in 1999. CJBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
160. MERIT-HF Trial Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF) Lancet 1999;535:2001-7.
161. Geijer RMM, Walma EP. Medicamenteuze behandeling van hartfalen. Een herwaardering van bèta-blokkers, spironolacton en digoxine. Huisarts Wet 2000;43:163-6.
162. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohaisi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
163. Fletcher AE. Adverse treatment effects in the trial of the European working party on high blood pressure in the elderly. Am J Med 1991;90:S42-4.
164. Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 1997;50:953-9.
165. Yarows SA, Staessen JA. How to use home blood pressure monitoring in clinical practice? Am J Hypertens 2002;15:93-6.
166. Brueren MM. Zelfmeting van bloeddruk in de huisartspraktilk: een overzicht. Tijdschr Huisartsgenecskd 2001;18:385-7.
167. Fletcher AE, Franks PJ, Bulpitt CJ. The effect of withdrawing antihypertensive therapy: a review. J Hypertension 1988;6:431-6.
168. Van Kruijsdijk M. Hypertensie opnieuw gemeten [Proefschrift]. Nijmegen: Katholieke Universiteit Nijmegen, 1991.
169. Walma E, Hoes AW, Van Dooren C, Prins A, Van der Does E. Withdrawal of long term diuretic medication in elderly patients: a double blind randomised trial. BMJ 1997;315:464-8.